ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Protalix Biotherapeutics, Inc." (PLX) Report Updated: Sep 01, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Protalix Biotherapeutics, Inc." (PLX)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: ENTA, FOLD, TKMR, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: F down downgrade
Last Week: D same upgrade
Two Weeks Ago: F up no change
service keys

"Protalix Biotherapeutics, Inc."© quotemedia

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, through Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. The company’s lead product candidate includes taliglucerase alfa, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which has completed Phase III clinical trial. It is also developing PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare genetic lysosomal disorder in humans; PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications; and PRX-106, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor and an antibody portion, which is developed as a treatment of various immune diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, spondylitis, psoriatic arthritis, and plaque psoriasis. The company’s product pipeline also includes an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher disease patients utilizing oral delivery of the recombinant enzyme produced within carrot cells; and two additional undisclosed therapeutic proteins, which are being evaluated in animal studies. It has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system; and research and license agreement with the Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

Recent News: "Protalix Biotherapeutics, Inc."